Filters
Cost of CAR-T in Major Cities of Switzerland
| City | Minimum Cost (USD) | Minimum Cost (CHF) | Maximum Cost (USD) | Maximum Cost (CHF) |
|---|---|---|---|---|
| Lustmuhle | USD 335700 | 278631 | USD 450000 | 373500 |
Need Help Planning Your Treatment Abroad?
Your 24/7 AI Health Assistant 
CAR T-cell therapy represents a groundbreaking approach to harnessing the power of the body's immune system to combat cancer. By modifying T cells, a subset of white blood cells, in a laboratory setting, these cells are empowered to recognize and eliminate cancer cells with precision. Often categorized as a form of cell-based gene therapy, CAR T-cell therapy involves altering the genetic makeup of T cells, equipping them with the ability to target specific cancer antigens.
This innovative treatment has demonstrated remarkable efficacy, particularly in cases where conventional therapies have proven ineffective. Its ability to reprogram the immune system to target and destroy cancer cells marks a significant advancement in cancer treatment strategies.
Classification:
CAR T cell therapy is classified as follows:
- Structure-based classification:
- First-generation CAR T-cells: These CAR T-cells typically consist of an antigen-binding domain (single-chain variable fragment, scFv) linked to a T-cell activation domain, such as the CD3ζ chain. They lack additional co-stimulatory domains.
- Second-generation CAR T-cells: These CAR T-cells include an additional co-stimulatory domain, such as CD28 or 4-1BB (CD137), along with the CD3ζ chain. The presence of co-stimulatory domains enhances T-cell activation and persistence.
- Third-generation CAR T-cells: These CAR T-cells incorporate two co-stimulatory domains along with the CD3ζ chain, aiming to further enhance T-cell function and anti-tumor activity.
Antigen-based classification: It includes
- CD19-targeted CAR T-cells: CD19 is a common target for CAR T-cell therapy and is used in the treatment of B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of lymphoma.
- Other antigen-targeted CAR T-cells: CAR T-cells can be engineered to target a variety of antigens expressed on cancer cells, including but not limited to BCMA (B-cell maturation antigen), CD22, CD30, and EGFRvIII.
CAR T-cell therapy is primarily used to treat blood cancers, such as multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukaemia. The patient's own T cells are reprogrammed to identify and destroy cancer cells, cause remission, enhance survival, and have a plan B in case other treatments fail.
Patients with blood cancers who relapsed or are refractory must consult an oncologist to determine candidacy for CAR T therapy, especially if they have failed to respond to traditional treatments (i.e., chemotherapy, radiation, or stem cell transplant). Evaluation is warranted for symptoms such as loss of weight, swelling of lymph nodes, recurrent infection, chronic fatigue, or spontaneous bruising.
Screening tests consist of imaging, bone marrow biopsy, and blood work.Leukapheresis is utilised to harvest T cells from the patient's blood for T-cell collection.Bridging therapy: Certain patients receive chemotherapy while waiting for CAR T cells to be produced.Lymphodepleting chemotherapy is administered before the injection to make room for CAR T cells. The patients should plan for potential hospitalisation, designate caretakers, and discuss long-term follow-up and expected adverse effects with the medical team.
- T-cell harvesting: T cells are removed from the patient's blood by processing.
- Genetic alteration: T cells are designed in the laboratory to express CAR proteins targeting cancer cells.
- Expansion: Modified T cells are expanded to therapeutic levels.
- Infusion: Patient receives an intravenous infusion of CAR T cells.
- Monitoring: Intensive monitoring, often in the hospital, for side effects and reactions.
The whole process, from cell harvesting to infusion, can take three to six weeks. The infusion itself takes a few hours to a few minutes, but for at least one week following the infusion, close monitoring is required, and there will be frequent follow-ups for several months.
- Cytokine Release Syndrome (CRS)
- Neurotoxicity
- Infections
- Low blood counts
- Relapse or non-response
One of the newer treatment options for some blood cancers is CAR T-cell therapy. It is utilised when other treatments are not working or the cancer recurs. CAR T-cell therapy has the potential to cure many blood cancers and extend life in most cases.
Recovery involves managing side effects like CRS and neurotoxicity, monitoring blood levels, and avoiding infections. Laboratory testing, imaging, and monitoring for late issues like hypogammaglobulinemia or relapse are all included in long-term follow-up.
The nature of the cancer, the burden of the disease, and an individual's response all impact success. For example, in pediatric acute lymphoblastic leukaemia, complete remission rates are more than 80%. However, relapse is always a risk, and long-term success is variable.
Would you like some help? We are available.
Get Help Explore Hospitals ( 1 )
Paracelsus Clinic
Lustmuhle, Switzerland
Apart from in-detail treatment procedures available, Paracelsus Clinic located in Lustmuhle, Switzerland has a wide variety of facilities available for International Patients. Some of the facilities which are provided by them are Accommodation, Airport Transfer, Choice of Meals, Interpreter, SIM, TV inside room. Also listed below are some of the most prominent infrastructural details:
- Five large buildings that caters to 8000+ outpatients every year
- Medical staff of the Hospital includes 5 Doctors, 2 Dentists, 40+ nurses
- Paracelsus Pharmacy
- Paracelsus Dentistry
- Culinarium/Restaurant
Need Some Advice From Our Experts?
Request a Call Back Now!
Our team of healthcare experts would be happy to assist you
+99Process Involved for CAR-T in Lustmuhle
- Preoperative Stage: An assessment of the patient's medical history, including testing to determine eligibility for CAR-T therapy and identify the target antigen on cancer cells.
- Treatment Plan Discussion: An oncologist discusses the procedure of CAR-T therapy, including potential dangers, advantages, and side effects.
- Therapeutic Stage: T-cells are extracted from the patient, modified in the lab to express a chimeric antigen receptor (CAR), and reintroduced into the patient to target and destroy cancer cells.
- Postoperative Phase: Closely monitor for side effects. Follow-ups are scheduled regularly to check the response and treat any complications.
- Cancer patients, especially those suffering from blood cancers like leukemia, lymphoma, and multiple myeloma.
- Patients who have not responded to previous therapies, such as chemotherapy or radiation.
- Patients in good overall health with a functioning immune system.
- Individuals who have specific genetic markers that qualify them for CAR-T treatment.
- Targeted Action: CAR-T treatment specifically targets cancer cells, increasing efficacy while minimising damage to healthy cells.
- Potential for Remission: Can result in long-term remission, even in people with difficult-to-treat cancer.
- Minimally Invasive: The treatment consists mainly of an outpatient procedure for T-cell collection, with the therapy provided via infusion.
- Fill out the inquiry form: Fill out the form to provide us with the relevant information about your condition.
- Consult with Our Healthcare Expert: One of our qualified specialists will contact you for a consultation.
- Receive a Detailed Treatment Plan: After examining your situation, we will provide you with a detailed treatment plan that includes expert views and cost breakdowns for various choices.
- Choose your preferred option: Choose the treatment option that suits you the best.
